Meta is investing hundreds of millions of dollars in Microsoft Azure AI services.

According to Bitget's market data, spot gold has fallen 1% intraday, currently trading at $4477.46 per ounce.

Karen Manner, fixed income strategist and portfolio manager at Hermes Investment Management, noted in a report that U.S. inflation remains the top concern for policymakers. Federal Reserve officials have maintained remarkable consistency on this point. Policymakers have also repeatedly stated that the current U.S. labor market is no longer considered a major source of inflationary pressure; instead, employment conditions are increasingly viewed as approaching balance. Consequently, the policy framework has shifted from concerns about the labor market to inflation as the primary variable.

Germany’s 5-year government bond yield rose by 1 basis point, hitting 3% for the first time since 2008.

Alibaba announced that its cloud computing arm Alibaba Cloud is undergoing a comprehensive upgrade to transition to an agent cloud model. Revenue growth for its artificial intelligence (AI) and cloud businesses will further accelerate in the coming quarters. Alibaba Group released its first-quarter fiscal 2027 financial results, during which group CEO Daniel Wu told analysts in a call that AI has become the core engine driving Alibaba Cloud’s accelerated growth. This quarter, Alibaba’s AI-related products hit an annualized run rate (ARR) of over RMB 49.5 billion (USD 7.3 billion), rising to account for 35% of Alibaba Cloud’s external commercial revenue. The gross profit margin of AI-related products is significantly higher than the average for cloud products.

Cronos Labs CEO Ryan Wyatt stated in a post that a re-examination of CRO’s token economics is needed. The team has extensive discussions and planning to carry out in the coming months, particularly regarding the buyback-and-burn mechanism tied to Cronos App revenue, community burns, and other related arrangements. All these items have been included in the project’s fourth-quarter (Q4) roadmap, with the full set of plans to be gradually unveiled at that time.

UBS has raised its price target for Moderna (MRNA.O) from $50 to $150. Earlier reports indicated that the personalized mRNA cancer vaccine co-developed by Moderna and Merck achieved major success in Phase 3 clinical trials for high-risk melanoma, becoming the world’s first mRNA cancer therapy proven effective in large-scale Phase 3 trials. After the announcement, Moderna’s stock price surged nearly 177% in a single day.